




Coagulation factor IX complex

Essential medicine status 

Section: [11. Blood products of human origin and plasma substitutes](#) > [11.2. Plasma-derived medicines](#) > [11.2.2. Blood coagulation factors](#)

EMLc

ATC codes: [B02BD01](#)

Indication	Coagulation defects, purpura or other haemorrhagic or related conditions ICD11 code: 3B6Z
Medicine type	Biological agent
List type	Complementary
Additional notes	All human plasma-derived medicines should comply with WHO requirements.
Formulations	Parenteral > General injections > IV: 500 IU in vial powder for injection ; 1000 IU in vial powder for injection
EML status history	First added in 1979 (TRS 641) Changed in 1989 (TRS 796) Changed in 2007 (TRS 950) Changed in 2013 (TRS 985) Changed in 2021 (TRS 1035)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Therapeutic alternatives to be reviewed (2023)
Therapeutic alternatives limitations for EMLc	Therapeutic alternatives to be reviewed (2023)
Patent information	Read more about patents. 
Wikipedia	Coagulation factor IX complex 
DrugBank	Coagulation factor ix, ii, vii, x (Factor IX Complex (Human)) 

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for coagulation factors be reviewed.

